10 Aug Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M, adding ABS-1230, a first-in-class therapy for rare KCNT1+ epilepsy....
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M, adding ABS-1230, a first-in-class therapy for rare KCNT1+ epilepsy....